Viridian Therapeutics, Inc.
Lumvoa
thyroid eye disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Lumvoa in thyroid eye disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Both the THRIVE and THRIVE-2 clinical trials met their respective primary and all secondary endpoints, consistently demonstrating statistically significant and clinically meaningful improvements at week 15 across all of the key signs and sy”